Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-09-08T10:29:51Z | - |
dc.date.available | 2021-09-08T10:29:51Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/118689 | - |
dc.description.abstract | Despite first-line therapy, most patients with advanced esophageal squamous cell carcinoma (ESCC) experience disease progression and may become eligible for second-line chemotherapy. Although commonly used, the role of salvage chemotherapy in patients with recurrent or metastatic ESCC has not yet been established. We analyzed 53 patients who had received second-line chemotherapy after the failure of cisplatin-based combination chemotherapy with or without radiotherapy as first-line therapy in ESCC between March 2000 and June 2008. Median progression-free survival (PFS) and overall survival (OS) for second-line chemotherapy were 2.4 and 5.2 months, respectively, with an overall response rate of 18.9%. In multivariate analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 2 or more and PFS under first-line therapy <4 months were independent prognostic factors for decreased OS. OS was estimated based on the number of adverse prognostic factors: 0 = good; 1 = intermediate, and 2 = poor. The median OS for the good, intermediate, and poor prognostic groups were 11.2, 4.5 and 4.3 months, respectively (p < 0.001). The good prognostic group showed better OS than the intermediate or poor groups (p < 0.001). Second-line chemotherapy may be beneficial for OS in ESCC patients with ECOG PS 0-1 and PFS under first-line therapy >= 4 months. Copyright (C) 2011 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | PHASE-II TRIAL | - |
dc.subject | CELL CARCINOMA | - |
dc.subject | COMBINATION CHEMOTHERAPY | - |
dc.subject | PLUS DOCETAXEL | - |
dc.subject | CANCER | - |
dc.subject | CISPLATIN | - |
dc.subject | 5-FLUOROURACIL | - |
dc.subject | IRINOTECAN | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | CAPECITABINE | - |
dc.title | Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seung Tae | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Shin, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1159/000322498 | - |
dc.identifier.scopusid | 2-s2.0-79952840480 | - |
dc.identifier.wosid | 000290377100008 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, v.79, no.5-6, pp.363 - 369 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.citation.title | ONCOLOGY | - |
dc.citation.volume | 79 | - |
dc.citation.number | 5-6 | - |
dc.citation.startPage | 363 | - |
dc.citation.endPage | 369 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | CELL CARCINOMA | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | PLUS DOCETAXEL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordAuthor | Chemotherapy, second line | - |
dc.subject.keywordAuthor | Esophageal squamous cell carcinoma | - |
dc.subject.keywordAuthor | Prognostic model | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.